CT-based Delta-radiomics Nomogram to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Patients
Overview
General Medicine
Affiliations
Background: This study developed a nomogram model using CT-based delta-radiomics features and clinical factors to predict pathological complete response (pCR) in esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy (nCRT).
Methods: The study retrospectively analyzed 232 ESCC patients who underwent pretreatment and post-treatment CT scans. Patients were divided into training (n = 186) and validation (n = 46) sets through fivefold cross-validation. 837 radiomics features were extracted from regions of interest (ROIs) delineations on CT images before and after nCRT to calculate delta values. The LASSO algorithm selected delta-radiomics features (DRF) based on classification performance. Logistic regression constructed a nomogram incorporating DRFs and clinical factors. Receiver operating characteristic (ROC) and area under the curve (AUC) analyses evaluated nomogram performance for predicting pCR.
Results: No significant differences existed between the training and validation datasets. The 4-feature delta-radiomics signature (DRS) demonstrated good predictive accuracy for pCR, with α-binormal-based and empirical AUCs of 0.871 and 0.869. T-stage (p = 0.001) and differentiation degree (p = 0.018) were independent predictors of pCR. The nomogram combined the DRS and clinical factors improved the classification performance in the training dataset (AUC = 0.933 and AUC = 0.941). The validation set showed similar performance with AUCs of 0.958 and 0.962.
Conclusions: The CT-based delta-radiomics nomogram model with clinical factors provided high predictive accuracy for pCR in ESCC patients after nCRT.
Cao P, Jia X, Wang X, Fan L, Chen Z, Zhao Y BMC Cancer. 2025; 25(1):443.
PMID: 40075375 PMC: 11899356. DOI: 10.1186/s12885-025-13823-8.
Xue J, Wu M, Zhang J, Yang J, Lv G, Qu B Front Oncol. 2025; 15:1523567.
PMID: 39944831 PMC: 11813761. DOI: 10.3389/fonc.2025.1523567.
Li H, Yuan Y, Xu Q, Liang G, Hu Z, Li X Front Immunol. 2024; 15:1487078.
PMID: 39635526 PMC: 11614804. DOI: 10.3389/fimmu.2024.1487078.
Li X, Dong J, Li B, Aimei O, Sun Y, Wu X Dose Response. 2024; 22(4):15593258241301525.
PMID: 39588071 PMC: 11587189. DOI: 10.1177/15593258241301525.
Li H, Zhang L, Song L, Wang Y, Song P, Ye Y Front Oncol. 2024; 14:1485323.
PMID: 39469635 PMC: 11513298. DOI: 10.3389/fonc.2024.1485323.